David A. Braun

7.4k total citations · 1 hit paper
92 papers, 2.0k citations indexed

About

David A. Braun is a scholar working on Pulmonary and Respiratory Medicine, Oncology and Cancer Research. According to data from OpenAlex, David A. Braun has authored 92 papers receiving a total of 2.0k indexed citations (citations by other indexed papers that have themselves been cited), including 63 papers in Pulmonary and Respiratory Medicine, 58 papers in Oncology and 34 papers in Cancer Research. Recurrent topics in David A. Braun's work include Renal cell carcinoma treatment (59 papers), Cancer Immunotherapy and Biomarkers (45 papers) and Cancer Genomics and Diagnostics (31 papers). David A. Braun is often cited by papers focused on Renal cell carcinoma treatment (59 papers), Cancer Immunotherapy and Biomarkers (45 papers) and Cancer Genomics and Diagnostics (31 papers). David A. Braun collaborates with scholars based in United States, United Kingdom and Canada. David A. Braun's co-authors include Toni K. Choueiri, Eliezer M. Van Allen, Catherine J. Wu, J. Bryan Iorgulescu, Derin B. Keskin, Ziad Bakouny, Kenneth J. Livak, Stuart C. Sealfon, Miguel Fribourg and Satyen H. Gohil and has published in prestigious journals such as New England Journal of Medicine, Journal of Biological Chemistry and Journal of Clinical Oncology.

In The Last Decade

David A. Braun

83 papers receiving 2.0k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Beyond conventional immune-checkpoint inhibition — novel immunotherapies for renal cell carcinoma

2021 224 citations David A. Braun, Ziad Bakouny et al. profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
David A. Braun United States	20	1.1k	942	878	587	445	92	2.0k
Fengshen Kuo United States	19	1.3k 1.3×	770 0.8×	819 0.9×	519 0.9×	789 1.8×	56	2.4k
Yongli Shuai United States	27	1.3k 1.3×	521 0.6×	814 0.9×	647 1.1×	736 1.7×	48	2.7k
Tarek Meniawy Australia	26	1.2k 1.1×	569 0.6×	639 0.7×	626 1.1×	455 1.0×	95	2.1k
Jaemoon Koh South Korea	29	1.5k 1.4×	1.0k 1.1×	600 0.7×	351 0.6×	687 1.5×	93	2.6k
Elaine T. Lam United States	18	677 0.6×	648 0.7×	621 0.7×	528 0.9×	189 0.4×	119	1.8k
María González‐Cao Spain	23	1.0k 1.0×	516 0.5×	659 0.8×	441 0.8×	384 0.9×	73	1.6k
Hiroko Asanuma Japan	32	1.4k 1.3×	520 0.6×	1.2k 1.4×	406 0.7×	782 1.8×	63	2.6k
Likun Hou China	24	846 0.8×	856 0.9×	597 0.7×	594 1.0×	264 0.6×	89	1.9k
Alex Martínez‐Martí Spain	20	1.3k 1.2×	1.2k 1.3×	418 0.5×	272 0.5×	330 0.7×	71	2.0k
Jonathan J. Havel United States	13	1.9k 1.8×	683 0.7×	825 0.9×	493 0.8×	1.1k 2.4×	14	2.7k

Countries citing papers authored by David A. Braun

Since Specialization

Citations

This map shows the geographic impact of David A. Braun's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by David A. Braun with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites David A. Braun more than expected).

Fields of papers citing papers by David A. Braun

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by David A. Braun. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by David A. Braun. The network helps show where David A. Braun may publish in the future.

Co-authorship network of co-authors of David A. Braun

This figure shows the co-authorship network connecting the top 25 collaborators of David A. Braun. A scholar is included among the top collaborators of David A. Braun based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with David A. Braun. David A. Braun is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Choueiri, Toni K., Thomas Powles, David A. Braun, et al.. (2024). 45 INTerpath-004: A phase 2, randomized, double-blind study of pembrolizumab with V940 (mRNA-4157) or placebo in the adjuvant treatment of renal cell carcinoma. The Oncologist. 29(Supplement_1). S15–S15. 3 indexed citations

Schoenfeld, David A., Dijana Djureinovic, David Su, et al.. (2024). Decoy-resistant IL-18 reshapes the tumor microenvironment and enhances rejection by anti–CTLA-4 in renal cell carcinoma. JCI Insight. 10(1). 6 indexed citations

Saliby, Renée Maria, Eddy Saad, Soki Kashima, David A. Schoenfeld, & David A. Braun. (2024). Update on Biomarkers in Renal Cell Carcinoma. American Society of Clinical Oncology Educational Book. 44(2). e430734–e430734. 16 indexed citations

Yekedüz, Emre, David A. Braun, Chris Labaki, et al.. (2024). 24 Applying genomic analysis to refine unclassified renal cell carcinoma. The Oncologist. 29(Supplement_1). S20–S20. 1 indexed citations

Ali, Muhammad, Renée Maria Saliby, Sharon Choi, et al.. (2024). Emerging Novel Functional Imaging and Immunotherapy in Renal Cell Carcinoma and Current Treatment Sequencing Strategies After Immunotherapy. American Society of Clinical Oncology Educational Book. 44(3). e438658–e438658. 3 indexed citations

Denize, Thomas, Maxine Sun, Renée Maria Saliby, et al.. (2024). Expression of the receptor tyrosine kinase AXL and clinical outcomes to cabozantinib and everolimus in patients with metastatic renal cell carcinoma enrolled in the METEOR trial.. Journal of Clinical Oncology. 42(16_suppl). 4543–4543. 2 indexed citations

Saad, Eddy, Chris Labaki, Renée Maria Saliby, et al.. (2024). 22 Association of a germline single nucleotide polymorphism (SNP) in the interleukin-7 (IL7) gene with immune-related adverse events (irAEs). The Oncologist. 29(Supplement_1). S1–S2.

Jilaveanu, Lucia B., Adebowale Adeniran, David Su, et al.. (2024). TIGIT expression in renal cell carcinoma infiltrating T cells is variable and inversely correlated with PD-1 and LAG3. Cancer Immunology Immunotherapy. 73(10). 192–192. 2 indexed citations

Bates, Anthony S., David A. Braun, Renu Eapen, et al.. (2024). Clinical Implications of Basic Research: Exploring the Transformative Potential of Spatial 'Omics in Uro-oncology. European Urology. 87(1). 8–14. 5 indexed citations

10.

Labaki, Chris, Renée Maria Saliby, Ziad Bakouny, et al.. (2023). Emerging Biomarkers of Response to Systemic Therapies in Metastatic Clear Cell Renal Cell Carcinoma. Hematology/Oncology Clinics of North America. 37(5). 937–942. 6 indexed citations

11.

Atkins, Michael B., Opeyemi A. Jegede, Naomi B. Haas, et al.. (2023). Phase II study of nivolumab and salvage nivolumab/ipilimumab in treatment-naïve patients with advanced non-clear cell renal cell carcinoma (HCRN GU16-260-Cohort B). Journal for ImmunoTherapy of Cancer. 11(3). e004780–e004780. 19 indexed citations

12.

Saad, Eddy, Renée Maria Saliby, Chris Labaki, et al.. (2023). Novel Immune Therapies for Renal Cell Carcinoma. Hematology/Oncology Clinics of North America. 37(5). 1027–1040. 1 indexed citations

13.

Anderson, Kristin G., David A. Braun, Aitziber Buqué, et al.. (2023). Leveraging immune resistance archetypes in solid cancer to inform next-generation anticancer therapies. Journal for ImmunoTherapy of Cancer. 11(6). e006533–e006533. 12 indexed citations

14.

Choueiri, Toni K., Amber C. Donahue, David A. Braun, et al.. (2023). Integrative Analyses of Tumor and Peripheral Biomarkers in the Treatment of Advanced Renal Cell Carcinoma. Cancer Discovery. 14(3). 406–423. 6 indexed citations

15.

Denize, Thomas, Yue Hou, Jean‐Christophe Pignon, et al.. (2022). Transcriptomic Correlates of Tumor Cell PD-L1 Expression and Response to Nivolumab Monotherapy in Metastatic Clear Cell Renal Cell Carcinoma. Clinical Cancer Research. 28(18). 4045–4055. 13 indexed citations

16.

Yang, Eddy S., Amin H. Nassar, Elio Adib, et al.. (2021). Gene Expression Signature Correlates with Outcomes in Metastatic Renal Cell Carcinoma Patients Treated with Everolimus Alone or with a Vascular Disrupting Agent. Molecular Cancer Therapeutics. 20(8). 1454–1461. 6 indexed citations

17.

Ficial, Miriam, Opeyemi A. Jegede, Yue Hou, et al.. (2020). Expression of T-Cell Exhaustion Molecules and Human Endogenous Retroviruses as Predictive Biomarkers for Response to Nivolumab in Metastatic Clear Cell Renal Cell Carcinoma. Clinical Cancer Research. 27(5). 1371–1380. 51 indexed citations

18.

Flaifel, Abdallah, Wanling Xie, David A. Braun, et al.. (2019). PD-L1 Expression and Clinical Outcomes to Cabozantinib, Everolimus, and Sunitinib in Patients with Metastatic Renal Cell Carcinoma: Analysis of the Randomized Clinical Trials METEOR and CABOSUN. Clinical Cancer Research. 25(20). 6080–6088. 48 indexed citations

19.

Cortese, Victor S., et al.. (2012). Case report - peracute to acute fatal pneumonia in cattle caused by Bibersteinia trehalosi.. The Bovine Practitioner. 46(2). 138–142. 6 indexed citations

20.

Hirshaut, Yashar, et al.. (1978). Levamisole as an immunoadjuvant: phase I study and application in breast cancer.. PubMed. 62(11). 1693–701. 3 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact